Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Horwitz

Showing results (601-610 of 717) with videos related to

Pageof 72
Sort By:
Blood Cancer Journal|June 17, 2021
Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapseSabela Bobillo, Erel Joffe, David Sermer, et al.
Advances in Radiation Oncology|September 12, 2018
Risk factors for late bowel and bladder toxicities in NRG Oncology prostate cancer trials of high-risk patients: A meta-analysis of physician-rated toxicitiesCanhua Xiao, Jennifer Moughan, Benjamin Movsas, et al.
European Urology|June 19, 2024
Corrigendum to "Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostat Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial" [Eur. Eurol. 84(2) (2023) 156-163]Oliver Sartor, Theodore G Karrison, Howard M Sandler, et al.
Molecular Psychiatry|October 20, 2019
Clinical, cortical thickness and neural activity predictors of future affective lability in youth at risk for bipolar disorder: initial discovery and independent sample replicationMichele A Bertocci, Lindsay Hanford, Anna Manelis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2021
Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA MonitoringCaitlin M Stewart, Laure Michaud, Karissa Whiting, et al.
Blood Advances|August 19, 2025
Association of PET4 Response With Outcomes of BV-CHP vs CHOP in the ECHELON-2 Trial in CD30+ Peripheral T-cell LymphomaSwaminathan P Iyer, Neha Mehta-Shah, Ranjana H Advani, et al.
Blood|December 19, 2013
A targeted mutational landscape of angioimmunoblastic T-cell lymphomaOreofe Odejide, Oliver Weigert, Andrew A Lane, et al.
European Urology|January 29, 2023
Effects of Androgen Deprivation Therapy on Prostate Cancer Outcomes According to Competing Event Risk: Secondary Analysis of a Phase 3 Randomised TrialLoren K Mell, Stephanie L Pugh, Christopher U Jones, et al.
International Journal of Radiation Oncology, Biology, Physics|January 2, 2023
Five-Year Patient-Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate CancerHimanshu R Lukka, Snehal Deshmukh, Deborah W Bruner, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 29, 2016
Patient-reported quality of life after stereotactic body radiation therapy versus moderate hypofractionation for clinically localized prostate cancerSkyler Bryce Johnson, Pamela R Soulos, Timothy D Shafman, et al.
Pageof 72

Showing results (601-610 of 717) with videos related to

Sort By:
Pageof 72
Blood Cancer Journal|June 17, 2021
Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapseSabela Bobillo, Erel Joffe, David Sermer, et al.
Advances in Radiation Oncology|September 12, 2018
Risk factors for late bowel and bladder toxicities in NRG Oncology prostate cancer trials of high-risk patients: A meta-analysis of physician-rated toxicitiesCanhua Xiao, Jennifer Moughan, Benjamin Movsas, et al.
European Urology|June 19, 2024
Corrigendum to "Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostat Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial" [Eur. Eurol. 84(2) (2023) 156-163]Oliver Sartor, Theodore G Karrison, Howard M Sandler, et al.
Molecular Psychiatry|October 20, 2019
Clinical, cortical thickness and neural activity predictors of future affective lability in youth at risk for bipolar disorder: initial discovery and independent sample replicationMichele A Bertocci, Lindsay Hanford, Anna Manelis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2021
Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA MonitoringCaitlin M Stewart, Laure Michaud, Karissa Whiting, et al.
Blood Advances|August 19, 2025
Association of PET4 Response With Outcomes of BV-CHP vs CHOP in the ECHELON-2 Trial in CD30+ Peripheral T-cell LymphomaSwaminathan P Iyer, Neha Mehta-Shah, Ranjana H Advani, et al.
Blood|December 19, 2013
A targeted mutational landscape of angioimmunoblastic T-cell lymphomaOreofe Odejide, Oliver Weigert, Andrew A Lane, et al.
European Urology|January 29, 2023
Effects of Androgen Deprivation Therapy on Prostate Cancer Outcomes According to Competing Event Risk: Secondary Analysis of a Phase 3 Randomised TrialLoren K Mell, Stephanie L Pugh, Christopher U Jones, et al.
International Journal of Radiation Oncology, Biology, Physics|January 2, 2023
Five-Year Patient-Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate CancerHimanshu R Lukka, Snehal Deshmukh, Deborah W Bruner, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 29, 2016
Patient-reported quality of life after stereotactic body radiation therapy versus moderate hypofractionation for clinically localized prostate cancerSkyler Bryce Johnson, Pamela R Soulos, Timothy D Shafman, et al.
Pageof 72